619f9224-823b-4edb-8035-c3193f37c3b8.pdf Press Release 27 June 2016 SalvaRx Group plc

("SalvaRx" or the "Company" or the "Group")

Final Results

SalvaRx (AIM:SALV), a biotechnology company focused on immunotherapy for cancer, today announces its Final Results for the year ended 31 December 2015.

On 22 March 2016, SalvaRx began trading on AIM following completion of the reverse takeover of 3Legs Resources plc and concurrent name change to SalvaRx Group plc.

3Legs Resources Period Highlights

  • Return of capital of approximately £1.1 million to Qualifying Shareholders following an Extraordinary General Meeting in February 2015

  • Investment of £500,000 received from Jim Mellon and Greg Bailey in June 2015, at which point both joined the Board as Non-­‐Executive Directors

  • Change in investing policy to investing in life sciences, as ratified at the Annual General Meeting in July 2015

  • Successful identification and investment for 11.1% of SalvaRx Limited in September 2015, an immuno-­‐oncology company which owns 60.5% of iOx, a University of Oxford spin out company using iNKT cells to target various cancers with a sponsored Phase I/II trial

    SalvaRx Post Period Highlights

  • iOx part of an international multi-­‐disciplinary consortium awarded a €8.3 million Horizon 2020 Grant for Phase I funding of another iOx compound IMM65 and a tumour vaccine developed by the Ludwig Institute for Cancer Research

  • Investment of $2 million for 9.2% stake in Intensity Therapeutics Inc. as part of a successful Series A fundraising, with proceeds being used for a Phase I trial to drive the development of Intensity's pioneering approach to treat solid tumours

Ian Walters, CEO of SalvaRx, commented: "2015 was a transformative year for the Group, which saw a repositioning of the investment policy to focus on Life Sciences, the investment in SalvaRx, and a clear path towards an RTO. In 2016, SalvaRx's subsidiary, iOx Therapeutics has made significant strides, doubling the number of planned clinical trials it is involved in and investing in a second technology platform in Intensity Therapeutics, which has shown significant potential in preclinical models and plans to treat its first cancer patient later this year. I am particularly pleased with how SalvaRx is positioned to achieve its initial targets at a fraction of the cost traditionally associated with this industry.

"As we continue to progress, I want to thank our new and existing shareholders who remained during the process of change seen within the business, and I look forward to continuing on the path towards a value inflection point for the Company. We hope to help the millions of people suffering with advanced cancers in a humane and more effective way in the future."

Availability of financial statements and AGM Notice

The Annual Report and Accounts for the year ended 31 December 2015 together with the Notice of Annual General Meeting will be posted to shareholders shortly and will be available on the Company's website www.salvarx.io.

The Annual General Meeting will be held at the Claremont Hotel, 18-­‐22 Loch Promenade, Douglas IM1 2LX at 13:00 on Thursday, 4 August 2016.

-­‐Ends-­‐ SalvaRx Group plc

Ian Walters (Chief Executive) Tel: +1 203 441 5451

Northland Capital Partners Limited

Nominated Adviser and Broker

Tel: +44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton (Corporate Finance) John Howes / Abigail Wayne (Corporate Broking)

Peterhouse Corporate Finance Limited

Joint Broker

Lucy Williams / Duncan Vasey

Tel: +44 (0) 20 7469 0932

Media enquiries: Abchurch Communications Limited

Alex Shaw / Abbie Warner/ Julian Bosdet Tel: +44 (0) 20 7398 7712

salvaRx@abchurch-­‐group.com www.abchurch-­‐group.com

Notes to Editors SalvaRx

SalvaRx was founded in 2014 to develop therapies within the rapidly growing immuno-­‐oncology market, which uses treatments designed to boost the body's natural defences to fight the cancer.

Immuno-­‐oncology therapy is a fast growing and new therapeutic area, a market expected to grow to

$80 billion worldwide by 2020 (Global & USA Cancer Immunotherapy Market Analysis 2020). SalvaRx's strategy is to invest in a portfolio of companies involved in novel cancer immunotherapies and develop them up to clinical proof of concept. SalvaRx provides portfolio companies with operational support in addition to capital, either by managing its portfolio companies directly or augmenting an existing team.

Though its investment in iOx, SalvaRx is developing, under licence from the Ludwig Institute, a series of small molecules for cancer immunotherapy. iOx has a clinical trial sponsorship agreement with the University of Oxford to fund the first in human Phase I/II clinical trial for its lead compound.

SalvaRx made the investment in Intensity Therapeutics with the intention to drive the development of Intensity's technology into the clinic and help fulfil SalvaRx's mission of promoting long term cancer survival using the body's own defence system. Intensity has a collaborative research agreement with the National Cancer Institute ("NCI") to explore new drugs and help determine their mechanism of action.

SalvaRx's management team have a proven track record of discovering and commercialising drugs in the area of cancer immunotherapy with Bristol-­‐Myers Squibb and Johnson & Johnson. The team is supported by an extended network of senior academic and industry executives to promote commercial and scientific outcomes, including licensing and partnering discussions.

For more information please visit: www.salvarx.io

SalvaRx Limited published this content on 27 June 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 June 2016 06:08:04 UTC.

Original documenthttp://www.salvarx.io/images/pdf/SalvaRx_Final_Results.pdf

Public permalinkhttp://www.publicnow.com/view/0748F1F8E860CCA61DD6B3EF3F7C6A0A85672EF4